Semaglutide does not cross the blood-brain barrier, yet it directly targets the brainstem, septal nucleus, and hypothalamus
Saliva substitutes are in the form of oral sprays, gels and rinses
TRIUMPH-4 (December 2025) TRIUMPH-1 (May 21, 2026) The consistency between TRIUMPH-4 (28.7%) and TRIUMPH-1 (28.3%) in different populations, different durations is exactly what the FDA looks for in a robust efficacy package
Retatrutide adds the glucagon component, which can contribute to increased heart rate and potential blood glucose fluctuations in some individuals
Compounded semaglutide (full dose), $219 / monthly supply
Participants were required to have a body mass index (BMI) of 27 kg/m or greater with at least one weight-related comorbidity, or a BMI of 30 kg/m or greater without comorbidities